212 related articles for article (PubMed ID: 18543899)
41. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of a New
Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932783
[TBL] [Abstract][Full Text] [Related]
43. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
44. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures.
Vasilaki A; Papadaki T; Notas G; Kolios G; Mastrodimou N; Hoyer D; Tsilimbaris M; Kouroumalis E; Pallikaris I; Thermos K
Invest Ophthalmol Vis Sci; 2004 May; 45(5):1499-506. PubMed ID: 15111608
[TBL] [Abstract][Full Text] [Related]
45. Somatostatin receptor targeting with hydrophilic [
Makris G; Kuchuk M; Gallazzi F; Jurisson SS; Smith CJ; Hennkens HM
Nucl Med Biol; 2019 Apr; 71():39-46. PubMed ID: 31129499
[TBL] [Abstract][Full Text] [Related]
46. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.
Reubi JC; Erchegyi J; Cescato R; Waser B; Rivier JE
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1551-8. PubMed ID: 20396884
[TBL] [Abstract][Full Text] [Related]
47. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
[TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Pelton JT; Kazmierski W; Gulya K; Yamamura HI; Hruby VJ
J Med Chem; 1986 Nov; 29(11):2370-5. PubMed ID: 2878079
[TBL] [Abstract][Full Text] [Related]
49. Identification and characterization of novel somatostatin antagonists.
Bass RT; Buckwalter BL; Patel BP; Pausch MH; Price LA; Strnad J; Hadcock JR
Mol Pharmacol; 1996 Oct; 50(4):709-15. PubMed ID: 8863814
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, Characterization, and In Vitro Evaluation of New (99m)Tc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach.
Li Y; Ma L; Gaddam V; Gallazzi F; Hennkens HM; Harmata M; Lewis MR; Deakyne CA; Jurisson SS
Inorg Chem; 2016 Feb; 55(3):1124-33. PubMed ID: 26789775
[TBL] [Abstract][Full Text] [Related]
51. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
52. N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity.
Rajeswaran WG; Hocart SJ; Murphy WA; Taylor JE; Coy DH
J Med Chem; 2001 Apr; 44(9):1416-21. PubMed ID: 11311064
[TBL] [Abstract][Full Text] [Related]
53. Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
Dalm VA; Hofland LJ; Mooy CM; Waaijers MA; van Koetsveld PM; Langerak AW; Staal FT; van der Lely AJ; Lamberts SW; van Hagen MP
J Nucl Med; 2004 Jan; 45(1):8-16. PubMed ID: 14734660
[TBL] [Abstract][Full Text] [Related]
54. Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Feuerbach D; Fehlmann D; Nunn C; Siehler S; Langenegger D; Bouhelal R; Seuwen K; Hoyer D
Neuropharmacology; 2000 Jun; 39(8):1451-62. PubMed ID: 10818261
[TBL] [Abstract][Full Text] [Related]
55. Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.
Valencak J; Heere-Ress E; Traub-Weidinger T; Raderer M; Schneeberger A; Thalhammer T; Aust S; Hamilton G; Virgolini I; Pehamberger H
Melanoma Res; 2005 Dec; 15(6):523-9. PubMed ID: 16314738
[TBL] [Abstract][Full Text] [Related]
56. SST3-selective potent peptidic somatostatin receptor antagonists.
Reubi JC; Schaer JC; Wenger S; Hoeger C; Erchegyi J; Waser B; Rivier J
Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13973-8. PubMed ID: 11095748
[TBL] [Abstract][Full Text] [Related]
57. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
58. Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan.
Erchegyi J; Hoeger CA; Low W; Hoyer D; Waser B; Eltschinger V; Schaer JC; Cescato R; Reubi JC; Rivier JE
J Med Chem; 2005 Jan; 48(2):507-14. PubMed ID: 15658864
[TBL] [Abstract][Full Text] [Related]
59. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
